RNS5 Dec 2022 07:09
An azacytidine-refractory acute myeloid leukemia (AML) patient with partial responses as communicated on October 31, 2022, achieved a complete remission, with incomplete blood cell count recovery after four treatment cycles. This was followed by full blood count recovery after five treatment cycles
Now that sounds very promising and would be a BOOM anywhere else!!